GNPX
Genprex, Inc.
Price Chart
Latest Quote
$0.52
-0.03 (-5.29%)
Current Price
| Previous Close | $0.55 |
| Open | $0.55 |
| Day High | $0.56 |
| Day Low | $0.52 |
| Volume | 153,158 |
Stock Information
| Shares Outstanding | 10.93M |
| Cash Equivalents | $18.05M |
| Net Income | $-16.73M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $5.69M |
| EPS (TTM) | $-5.06 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-12.53M |
| Income | $-16.73M |
| Book/sh | $1.87 |
| Cash/sh | $1.65 |
| Employees | 13 |
Financial Ratios
| Quick Ratio | 5.38 |
| Current Ratio | 5.61 |
Returns & Margins
| ROA | -76.19% |
| ROE | -160.84% |
Ownership
| Insider Ownership | 0.97% |
| Institutional Ownership | 0.99% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.24 |
| P/B | 0.28 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.65 |
| SMA50 | $0.84 |
| SMA200 | $3.98 |
| RSI | 32.46 |
| ATR | 0.0658 |
| Shares Float | 10.56M |
| Short Float | 9.24% |
| Short Ratio | 2.66 |
| Volatility | -0.96 |
| Rel Volume | 0.38 |
Performance History
| Week | +6.98% |
| Month | -36.07% |
| Quarter | -72.72% |
| 6 Months | -75.99% |
| YTD | -70.89% |
| Year | -96.05% |
| 3 Years | -99.97% |
| 5 Years | -99.99% |
| 10 Years | -99.99% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $0.52 | 156,200 |
| 2026-06-22 | $0.55 | 351,300 |
| 2026-06-18 | $0.59 | 1,609,100 |
| 2026-06-17 | $0.48 | 708,000 |
| 2026-06-16 | $0.44 | 431,900 |
| 2026-06-15 | $0.49 | 1,620,000 |
| 2026-06-12 | $0.64 | 183,800 |
| 2026-06-11 | $0.65 | 127,900 |
| 2026-06-10 | $0.64 | 109,100 |
| 2026-06-09 | $0.67 | 176,400 |
| 2026-06-08 | $0.67 | 195,800 |
| 2026-06-05 | $0.65 | 443,400 |
| 2026-06-04 | $0.69 | 186,100 |
| 2026-06-03 | $0.72 | 185,700 |
| 2026-06-02 | $0.74 | 202,200 |
| 2026-06-01 | $0.75 | 404,800 |
| 2026-05-29 | $0.78 | 270,700 |
| 2026-05-28 | $0.80 | 341,000 |
| 2026-05-27 | $0.78 | 202,300 |
| 2026-05-26 | $0.77 | 414,900 |
About Genprex, Inc.
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. It also develops REQORSA Gene Therapy in Mesothelioma, Ras Inhibitor Resistant NSCLC, other tumor suppressor genes, and Glioblastoma, which is in preclinical studies. Its three-lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive; New York University; UTHealth Houston; and University of Pittsburgh. The company also has a sponsored research agreement with The University of Texas MD Anderson Cancer Center to study biomarkers that for the prediction of patient response to Reqorsa Gene Therapy. Genprex, Inc. was incorporated in 2009 and is based in Austin, Texas.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $739,935 | $0 | - | - |
| Total Expenses | $15,515,619 | $21,174,167 | $31,056,894 | $23,830,719 |
| Other Income Expense | $26,601 | $63,004 | $-18,676 | - |
| Other Non Operating Income Expenses | $26,601 | $63,004 | $-18,676 | - |
| Net Non Operating Interest Income Expense | $-739,935 | $0 | $215,109 | $90,098 |
| Interest Expense Non Operating | $739,935 | $0 | - | - |
| Operating Expense | $15,515,619 | $21,174,167 | $31,056,894 | $23,830,719 |
| General And Administrative Expense | $6,086,899 | $10,632,028 | $13,425,285 | $12,295,070 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-16,228,953 | $-21,111,163 | $-30,860,461 | $-23,740,621 |
| Net Interest Income | $-739,935 | $0 | $215,109 | $90,098 |
| Normalized Income | $-16,228,953 | $-21,111,163 | $-30,860,461 | $-23,740,621 |
| Net Income From Continuing And Discontinued Operation | $-16,228,953 | $-21,111,163 | $-30,860,461 | $-23,740,621 |
| Total Operating Income As Reported | $-15,515,619 | $-21,174,167 | $-31,056,894 | $-23,830,719 |
| Net Income Common Stockholders | $-16,228,953 | $-21,388,282 | $-30,860,461 | $-23,740,621 |
| Net Income | $-16,228,953 | $-21,111,163 | $-30,860,461 | $-23,740,621 |
| Net Income Including Noncontrolling Interests | $-16,228,953 | $-21,111,163 | $-30,860,461 | $-23,740,621 |
| Net Income Continuous Operations | $-16,228,953 | $-21,111,163 | $-30,860,461 | $-23,740,621 |
| Pretax Income | $-16,228,953 | $-21,111,163 | $-30,860,461 | $-23,740,621 |
| Operating Income | $-15,515,619 | $-21,174,167 | $-31,056,894 | $-23,830,719 |
| Depreciation Amortization Depletion Income Statement | $0 | $6,693 | $15,004 | $25,575 |
| Depreciation And Amortization In Income Statement | $0 | $6,693 | $15,004 | $25,575 |
| Depreciation Income Statement | $0 | $6,693 | $15,004 | $25,575 |
| Interest Income | - | $63,574 | $215,109 | $90,098 |
| Interest Income Non Operating | - | $63,574 | $215,109 | $90,098 |
| Per Share | ||||
| Diluted EPS | $-17.40 | $-266.89 | $-22.56 | $-990.00 |
| Basic EPS | $-17.40 | $-266.89 | $-22.56 | $-990.00 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-15,489,018 | $-21,104,470 | $-31,041,890 | $-23,805,144 |
| Reconciled Depreciation | $0 | $6,693 | $15,004 | $25,575 |
| EBITDA (Bullshit earnings) | $-15,489,018 | $-21,104,470 | $-31,041,890 | $-23,805,144 |
| EBIT | $-15,489,018 | $-21,111,163 | $-31,056,894 | $-23,830,719 |
| Diluted Average Shares | $932,730 | $80,139 | $1,367,747 | $1,198,837 |
| Basic Average Shares | $932,730 | $80,139 | $1,367,747 | $1,198,837 |
| Diluted NI Availto Com Stockholders | $-16,228,953 | $-21,388,282 | $-30,860,461 | $-23,740,621 |
| Otherunder Preferred Stock Dividend | $0 | $277,119 | - | - |
| Research And Development | $9,428,720 | $10,535,446 | $17,616,605 | $11,510,074 |
| Selling General And Administration | $6,086,899 | $10,632,028 | $13,425,285 | $12,295,070 |
| Other Gand A | $6,086,899 | $10,632,028 | $13,425,285 | $12,295,070 |
Fetched: 2026-06-22
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $7,961,876 | $1,620,155 | $6,642,906 | $21,572,645 |
| Total Assets | $10,159,011 | $4,124,325 | $10,670,592 | $25,085,027 |
| Total Non Current Assets | $1,802,228 | $2,046,858 | $3,138,825 | $3,611,882 |
| Other Non Current Assets | $1,802,228 | $2,046,858 | $2,347,488 | $2,864,937 |
| Current Assets | $8,356,783 | $2,077,467 | $7,531,767 | $21,473,145 |
| Other Current Assets | $525,928 | $475,807 | $794,138 | $484,224 |
| Cash Cash Equivalents And Short Term Investments | $7,830,855 | $1,601,660 | $6,737,629 | $20,954,069 |
| Cash And Cash Equivalents | $7,830,855 | $1,601,660 | $6,737,629 | $20,954,069 |
| Cash Financial | $7,830,855 | $1,601,660 | - | $20,954,069 |
| Non Current Prepaid Assets | - | $0 | $10,000 | $21,818 |
| Goodwill And Other Intangible Assets | - | $0 | $773,478 | $702,095 |
| Other Intangible Assets | - | - | $773,478 | $702,095 |
| Receivables | - | - | $0 | $34,852 |
| Accounts Receivable | - | - | $0 | $34,852 |
| Prepaid Assets | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,197,135 | $2,504,170 | $3,254,208 | $2,810,287 |
| Total Non Current Liabilities Net Minority Interest | $22,500 | $0 | $0 | $0 |
| Derivative Product Liabilities | $22,500 | $0 | - | - |
| Current Liabilities | $2,174,635 | $2,504,170 | $3,254,208 | $2,810,287 |
| Other Current Liabilities | $1,431,565 | $1,429,875 | $1,856,598 | $2,367,362 |
| Payables And Accrued Expenses | $743,070 | $1,074,295 | $1,397,610 | $442,925 |
| Payables | $743,070 | $1,074,295 | $1,397,610 | $442,925 |
| Accounts Payable | $743,070 | $1,074,295 | $1,397,610 | $442,925 |
| Equity | ||||
| Common Stock Equity | $7,961,876 | $1,620,155 | $7,416,384 | $22,274,740 |
| Total Equity Gross Minority Interest | $7,961,876 | $1,620,155 | $7,416,384 | $22,274,740 |
| Stockholders Equity | $7,961,876 | $1,620,155 | $7,416,384 | $22,274,740 |
| Retained Earnings | $-171,028,396 | $-154,799,443 | $-133,688,280 | $-102,827,819 |
| Other | ||||
| Ordinary Shares Number | $3,291,488 | $10,860,655 | $1,485,902 | $1,202,649 |
| Share Issued | $3,291,488 | $10,860,655 | $1,485,902 | $1,202,649 |
| Tangible Book Value | $7,961,876 | $1,620,155 | $6,642,906 | $21,572,645 |
| Invested Capital | $7,961,876 | $1,620,155 | $7,416,384 | $22,274,740 |
| Working Capital | $6,182,148 | $-426,703 | $4,277,559 | $18,662,858 |
| Total Capitalization | $7,961,876 | $1,620,155 | $7,416,384 | $22,274,740 |
| Additional Paid In Capital | $178,986,981 | $156,419,381 | $141,103,178 | $125,101,356 |
| Capital Stock | $3,291 | $217 | $1,486 | $1,203 |
| Common Stock | $3,291 | $217 | $1,486 | $1,203 |
| Preferred Stock | $0 | $0 | $0 | - |
| Net PPE | $0 | $0 | $7,859 | $23,032 |
Fetched: 2026-06-22
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-15,311,209 | $-17,922,566 | $-24,809,986 | $-17,681,233 |
| Operating Activities | ||||
| Operating Cash Flow | $-15,311,209 | $-17,922,566 | $-24,738,603 | $-17,621,498 |
| Cash Flow From Continuing Operating Activities | $-15,311,209 | $-17,922,566 | $-24,738,603 | $-17,621,498 |
| Investing Activities | ||||
| Investing Cash Flow | $0 | $774,644 | $-71,214 | $-59,735 |
| Cash Flow From Continuing Investing Activities | $0 | $774,644 | $-71,214 | $-59,735 |
| Capital Expenditure | - | - | $-71,383 | $-59,735 |
| Net Other Investing Changes | - | - | - | $1 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $21,540,404 | $12,011,953 | $10,593,377 | $6,426 |
| Financing Cash Flow | $21,540,404 | $12,011,953 | $10,593,377 | $6,426 |
| Cash Flow From Continuing Financing Activities | $21,540,404 | $12,011,953 | $10,593,377 | $6,426 |
| Net Common Stock Issuance | $21,540,404 | $12,011,953 | $10,593,377 | $6,426 |
| Common Stock Issuance | $21,540,404 | $12,011,953 | $10,593,377 | $6,426 |
| Other | ||||
| End Cash Position | $7,830,855 | $1,601,660 | $6,737,629 | $20,954,069 |
| Beginning Cash Position | $1,601,660 | $6,737,629 | $20,954,069 | $38,628,876 |
| Changes In Cash | $6,229,195 | $-5,135,969 | $-14,216,440 | $-17,674,807 |
| Net Intangibles Purchase And Sale | $0 | $773,478 | $-71,383 | $-59,735 |
| Sale Of Intangibles | $0 | $773,478 | - | $157,465 |
| Net PPE Purchase And Sale | $0 | $1,166 | $169 | $0 |
| Sale Of PPE | $0 | $1,166 | $169 | $0 |
| Change In Working Capital | $-135,026 | $-121,078 | $698,126 | $1,361,604 |
| Change In Other Current Liabilities | $1,690 | $-426,723 | $-510,765 | $1,755,262 |
| Change In Other Current Assets | $244,630 | $300,630 | $517,449 | $157,465 |
| Change In Payables And Accrued Expense | $-331,226 | $-323,315 | $954,686 | $-530,269 |
| Change In Payable | $-331,226 | $-323,315 | $954,686 | $-530,269 |
| Change In Account Payable | $-331,226 | $-323,315 | $954,686 | $-530,269 |
| Change In Prepaid Assets | $-50,120 | $328,330 | $-298,096 | $13,998 |
| Other Non Cash Items | $739,935 | $773,478 | - | $-1 |
| Stock Based Compensation | $312,835 | $3,302,982 | $5,408,728 | $4,731,944 |
| Depreciation Amortization Depletion | $0 | $6,693 | $15,004 | $25,575 |
| Depreciation And Amortization | $0 | $6,693 | $15,004 | $25,575 |
| Depreciation | $0 | $6,693 | $15,004 | $25,575 |
| Net Income From Continuing Operations | $-16,228,953 | $-21,111,163 | $-30,860,461 | $-23,740,621 |
| Purchase Of Intangibles | - | $0 | $-71,383 | $-59,735 |
| Change In Receivables | - | $0 | $34,852 | $-34,852 |
| Changes In Account Receivables | - | $0 | $34,852 | $-34,852 |
| Change In Other Working Capital | - | - | $517,449 | $157,465 |
| Purchase Of PPE | - | - | - | $0 |
Fetched: 2026-06-22